未登录

S

Spencer Bujarski

University of California System

H指数:27

被引数:1,936

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lifetime heavy drinking years predict alcohol use disorder severity over and above current alcohol use

AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

IF2.6

2021-06-167

OAAI

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial

TRANSLATIONAL PSYCHIATRY

IF6.2

2021-06-1254

OAAI

Do behavioral pharmacology findings predict clinical trial outcomes? A proof-of-concept in medication development for alcohol use disorder

NEUROPSYCHOPHARMACOLOGY

IF7.1

2020-11-2417

OAAI

Modeling motivation for alcohol in humans using traditional and machine learning approaches

ADDICTION BIOLOGY

IF2.6

2020-07-296

OAAI

Capturing habitualness of drinking and smoking behavior in humans

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2020-02-0119

OAAI

Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use

酒精，烟草和大麻的消费与当天物质共使用和三次使用的几率增加有关

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2019-07-0185

OAAI

Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2019-07-019

OAAI

Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis

ADDICTION BIOLOGY

IF2.6

2019-05-3037

OAAI

Differences in the subjective and motivational properties of alcohol across alcohol use severity: application of a novel translational human laboratory paradigm

NEUROPSYCHOPHARMACOLOGY

IF7.1

2018-05-0840

OAAI

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH

IF2.7

2018-02-0115

OAAI

Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder

PSYCHOPHARMACOLOGY

IF3.3

2017-03-2917

OAAI

Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial

NEUROPSYCHOPHARMACOLOGY

IF7.1

2017-01-16103

OAAI

Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research

BEHAVIOUR RESEARCH AND THERAPY

IF4.5

2016-11-0130

OAAI

Relationship between negative affect and smoking topography in heavy drinking smokers

ADDICTIVE BEHAVIORS

IF3.6

2016-10-013

OAAI

Functional significance of subjective response to alcohol across levels of alcohol exposure

不同酒精暴露水平下对酒精的主观反应的功能意义

ADDICTION BIOLOGY

IF2.6

2015-08-1028

PREAI

Emotion differentiation and intensity during acute tobacco abstinence: A comparison of heavy and light smokers

ADDICTIVE BEHAVIORS

IF3.6

2015-08-0131

OAAI

Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

IF2.5

2015-07-0119

OAAI

The Association of Alcohol Severity and Sleep Quality in Problem Drinkers

ALCOHOL AND ALCOHOLISM

IF2.2

2015-05-2744

OAAI

Factor Structure of Subjective Responses to Alcohol in Light and Heavy Drinkers

aging clinical and experimental research

IF3

2015-05-2234

OAAI

Mechanisms of topiramate effects: refining medications development for alcoholism

ADDICTION BIOLOGY

IF2.6

2015-04-163

PREAI